Recall: D-0806-2026

Class II - Potentially Harmful

Class IIClassification

2026-08-06Initiated

OngoingStatus

Baxter Healthcare CorporationFirm

Product

MYXREDLIN, Insulin Human in 0.9% Sodium Chloride Injection, 100 units/100 mL (1 unit/mL), Rx only, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-0126-12.

Reason

CGMP Deviations

Distribution

US Nationwide; Puerto Rico; and Chile.

Source: FDA drug enforcement report via openFDA (Voluntary: Firm initiated). If you take this product, talk to your pharmacist or doctor before stopping it.